Novo Nordisk(US:NVO) GLP1减重宝典·2025-07-19 04:59Core Viewpoint - The long-term study of Wegovy (semaglutide) demonstrates its effectiveness in weight management and cardiovascular benefits for overweight or obese patients with cardiovascular diseases, showing an average weight loss of approximately 10% over four years with sustained results for 65 weeks without rebound [2][6][13]. Study Design - The SELECT trial, the longest clinical trial to date, involved 17,604 participants from 41 countries, assessing the impact of Wegovy versus placebo over four years [5][9]. - The primary endpoint was the time to the first occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [10]. Efficacy of Wegovy - Results indicated that 67.8% of participants in the Wegovy group lost 5% or more of their body weight, compared to 21.3% in the placebo group. The percentages for losing 10%, 15%, 20%, and 25% were 44.2%, 22.9%, 11%, and 4.9% respectively, versus 6.9%, 1.7%, 0.6%, and 0.1% in the placebo group [11]. - After 104 weeks, approximately 52.4% of Wegovy patients showed improvement in BMI, while only 15.7% in the placebo group did [11]. Weight Loss and Measurements - The average weight loss in the Wegovy group was 10.2%, with a waist circumference reduction of 7.7 cm, compared to a 1.5% weight loss and 1.3 cm reduction in the placebo group [13]. - The waist-to-height ratio decreased by 6.9% in the Wegovy group, while the placebo group saw a decrease of 1.0% [13]. Side Effects - 16.6% of patients in the Wegovy group discontinued due to adverse events, compared to 8.2% in the placebo group. Serious adverse events were reported by approximately 33.4% in the Wegovy group and 36.4% in the placebo group [14]. - The study found a lower association of serious adverse events with Wegovy, particularly those related to cardiovascular diseases or infections [14]. Future Research - The SELECT Life trial will follow participants from the SELECT trial to gather long-term data on the effects of Wegovy [16].